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Abstract
Background: Patients with solid malignant tumours are at increased risk of Pneumocystis jiroveci
infection from immunosuppression as a result of chemotherapy and/or radiotherapy, but active
Pneumocystis pneumonia (PCP) in untreated lung cancer is uncommon.
Case presentation: A 43-year-old woman presented with prolonged fever, progressive
dyspnoea, diffuse alveolar and interstitial infiltrates. Malignant cells were found on sputum cytology,
confirming the diagnosis of lung cancer. She had been treated with corticosteroids and antibiotics
but did not receive chemotherapy or radiotherapy. Pneumocystis jiroveci was later found in the
sputum but she proved to be HIV negative.
Conclusion:  Unsuspected PCP can occur in chemotherapy and radiotherapy-naïve, HIV-
seronegative patients with lung cancer. The complex clinicoradiological manifestations of PCP with
underlying lung cancer can lead to delay in diagnosis and may worsen the prognosis.
Background
Pneumocystis jiroveci pneumonia (PCP, formerly known
as Pneumocystis carinii  pneumonia) has been increas-
ingly reported as a severe opportunistic infection in HIV-
seronegative patients with solid tumours (brain, lung,
breast and ovarian cancer), as a sequel to severe immuno-
suppression from chemotherapy and/or radiotherapy
with or without corticosteroids [1-5].
We present a case of unsuspected PCP in an HIV-seroneg-
ative patient with untreated lung cancer, manifested as
persistent fever, progressive dyspnoea, and diffuse alveo-
lar and interstitial infiltrates.
Case presentation
A 43-year-old nonsmoking female was referred to our
hospital for persistent fever, progressive dyspnoea, and
diffuse alveolar and interstitial infiltrates. The patient
complained of intermittent mild to moderate fever, pro-
gressive dyspnoea, increasing exportation and paroxysmal
wheezing for 6 weeks. Her past history was unremarkable,
without known exposure to occupational or environmen-
tal hazards. She was initially diagnosed as community
acquired pneumonia in her local hospital, treated with
intravenous levofloxacin, which was escalated to cephatri-
axone when her symptoms worsened. Intravenous dex-
amethasone (10 mg to 20 mg prn) with aminophylline
was administered irregularly to relieve her dyspnoea and
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wheezing. She developed orthopnoea with high fever and
copious gel-like phlegm four weeks after the onset of
symptoms, so she was transferred to our hospital.
On admission, she displayed orthopnoea, cyanosis, finger
clubbing and nonpitting edoema in the lower extremities.
Vital signs: body temperature 38.8°C, HR 124 beats/min,
respiratory rate 32 breath/min, and Bp 124/76 mmHg.
Fine crackles were audible at both bases with resonant
wheezing throughout inspiration and expiration. Superfi-
cial lymph nodes, heart and abdomen were unremarka-
ble.
Laboratory workup: complete blood count revealed WBC
elevation with WBC 15.4 ×109/L, granulocytes 86%, lym-
phocytes 14%, RBC and PLT were in normal range. Serum
liver and renal biochemistry as well as electrolytes were
unremarkable. Serum CEA 13.4 µg/L (0–5 µg/L), D-dimer
680 ng/mL (< 200 ng/mL). Arterial blood gas analysis
(nasal oxygen, 3 L/min): pH 7.42, PaO26.54 kPa, PaCO2
3.86 kPa.
Chest radiograph (Fig. 1) revealed diffuse nodular and
patchy consolidations with predominance in the lower
lung fields, and right hilar expansion. Chest CT scanning
(Fig. 2) demonstrated diffuse alveolar and interstitial
infiltrates with partial confluence and adenopathy in both
hilar regions. CT angiography was negative for pulmonary
embolism.
Diffuse bronchioloalveolar carcinoma (BAC) complicated
by acute respiratory failure was suspected, malignancy was
confirmed with evidence of malignant cells repeatedly
found in sputum smears examined by a lung pathologist
(Dr Gu YY). Intubation and invasive mechanical ventila-
tion was strongly recommended because of her critical
condition, but was declined by the patient and her family.
Non-invasive ventilation (CPAP) was given as an alterna-
tive to treat the respiratory failure, with imipenem/cilastin
to target the suspected bacterial pneumonia. Her orthop-
noea and high fever remained despite treatment, with
peripheral WBC elevated to 22.6 × 109/L, granulocytes
95%, lymphocytes 5%, yet repeated blood and sputum
cultures for bacteria were negative. Empiric vancomycin
was added for possible gram-positive cocci infections to
no avail.
Four days after admission, clusters of Pneumocystis
jiroveci cysts were unexpectedly and repeatedly identified
in her sputa using methamine silver stain (Fig. 3). The
patient was therefore diagnosed with PCP. Oral TMP-SMX
(2 double-strength tab, tid, as intravenous pentamdine or
trimethoprim/sulfamethoxazole was not available in
Guangzhou), with intravenous methylprednisolone 40
mg qd as adjunctive therapy, was initiated with the origi-
nal antibiotic regimen still continued. Further investiga-
tions found that her peripheral blood CD4 T lymphocyte
was 189/µL with CD4/CD8 ratio as 1.4: 1, C reactive pro-
tein (CRP) was 26 mg/L (0–8 mg/L), serum lactate dehy-
drogenase (LDH) was 371 IU/L (35–90 IU/L). She tested
negative for HIV and cytomegalovirus. Her family mem-
bers including her husband and children were also HIV-
seronegative. When 7 days' treatment with co-trimoxazole
Chest CT displaying diffuse nodular parenchymal infiltrates  with partial confluence Figure 2
Chest CT displaying diffuse nodular parenchymal infiltrates 
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Chest radiograph showing diffuse nodular and patchy pulmo- nary infiltrates, and right hilar widening Figure 1
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failed to alleviate her respiratory distress and high fever,
her family opted to withdraw her from therapy and
obtained her discharge. She died of respiratory failure
three days later.
Discussion
The patient presented with progressive dyspnoea, copious
glutinous sputum, diffuse alveolar and interstitial infil-
trates on chest radiograph and CT. These are consistent
with the clinicoradiological features of the diffuse form of
BAC [6]. In addition, with the cytological evidence of
malignancy, a clinical diagnosis of diffuse form of BAC
could be reached. However, as the definitive diagnosis of
BAC requires histological evidence of malignancy from
resected or biopsied lung tissues, whereas in the present
case, invasive procedures such as transbronchial lung
biopsy were precluded due to the patient's critical condi-
tion and lack of invasive mechanical ventilation to ensure
reliable oxygenation. So, for this patient, the appropriate
diagnosis is lung cancer, most likely, diffuse form of BAC.
PCP is relatively uncommon in lung cancer, as a sequel to
immunosuppression, it had been reported sporadically in
lung cancer patients [3,7]. All these patients had under-
gone chemotherapy or radiotherapy with or without cor-
ticosteroids, before the onset of PCP. Recently, Maskell et
al revealed asymptomatic colonization of Pneumocystis
jiroveci in lung cancer patients by fibrobronchoscopy, and
de la Horra et al identified 12 cases of unsuspected sub-
clinical Pneumocystis jiroveci infection using polymerase
chain reaction in fixed lung samples from hospitalized
patients died of lung carcinoma untreated by radiother-
apy or chemotherapy [8,9]. To our knowledge, the present
case is the first to document active unsuspected PCP in an
untreated, HIV- seronegative patient with lung cancer.
Though fever, dry cough and progressive dysponea with
pulmonary infiltrates of alveolar pattern are typical of
PCP, these manifestations are nonspecific. Definitive
diagnosis of PCP requires identification of Pneumocystis
jiroveci in respiratory secretions, bronchial alveolar lavage
fluid or biopsied lung tissues [1,10]. When the presenta-
tion is complicated by the presence of underlying lung
cancer, the diagnosis of PCP becomes more challenging as
the clinical picture becomes more atypical and confusing.
In the present case, the differential diagnosis for the fever,
orthopnoea and diffuse alveolar and interstitial infiltrates,
should include other superimposed infections, pulmo-
nary embolism and broncholymphatic dissemination of
the neoplasm. Both PCP and advanced lung cancer might
have contributed to progressive dyspnoea and refractory
respiratory failure, as well as the radiological pattern of
infiltrates, but the manifestation of copious glutinous
sputum is atypical of PCP, and points to lung cancer, most
possibly BAC.
Although this HIV-seronegative patient was radiotherapy
and chemotherapy naïve, she displayed impaired cellular
immunity with significant reduction of peripheral CD4 T
lymphocytes. This lymphocytic subset is believed to play
a crucial role in the pathogenesis of PCP by orchestrating
host immune response responsible for eradication of
Pneumocystis jiroveci. Reduction of peripheral CD4 T lym-
phocytes below 200/µL is associated with a higher inci-
dence of PCP in both AIDS and non-AIDS patients
[1,10,11]. The mechanism for CD4 T lymphocyte decline
without lymphopenia in this patient was unclear, the pre-
ceding exposure to high dose dexamethasone might have
been an important contributing factor, since corticoster-
oids can reduce CD4 T lymphocytes numbers and inhibit
their functions [1,2,10], thus an important risk factor for
colonization of Pneumocystis jiroveci  in patients with
chronic obstructive pulmonary disease or lung cancer [8].
And chronic steroid therapy in patients with brain
tumours, connective collagen diseases, or even in child
with asthma, is frequently associated with active PCP, as a
complication of severe immunosuppression from pro-
longed steroid use [1,2,8,12]. In addition, host cellular
immunity may be compromised by neoplasms which
inhibit the activation of T lymphocytes [13].
Severe cellular immunodeficiency resulting from systemic
corticosteroids treatment must have led to activation of
latent Pneumocystis jiroveci infection in our patient, as
recent evidence suggests that approximately 20% of
patients with chronic lung diseases including lung cancer
are asymptomatic carriers of Pneumocystis jiroveci  [8],
which progressed to severe active PCP following high-
Methamine silver stain demonstrating clusters of Pneumo- cystis jiroveci cysts in the sputum (×100) Figure 3
Methamine silver stain demonstrating clusters of Pneumo-
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dose dexamethasone treatment, since other transmission
pathways, such as nosocomial infection or cross-transmis-
sion among family members were less likely.
As this case demonstrates, significant increase of LDH and
CRP reflecting severe systematic inflammation, and severe
hypoxemia requiring mechanical ventilation may be asso-
ciated with a poor clinical outcome. These parameters
have been reported to be prognostic predictors of PCP
[1,10,14].
Possible resistance to co-trimoxazole by infective Pneu-
mocystis jiroveci, concurrent bacterial infections, progres-
sion of advanced carcinoma especially by
broncholymphatic dissemination might also have con-
tributed to the treatment failure.
Despite the increasing awareness of active PCP in severely
immunosuppressed non-AIDS patients, unsuspected PCP
cases are still not uncommon due to an increase in the sus-
ceptible population, and the complexities of diagnosis,
especially when masked by the manifestations of underly-
ing diseases and their complications. For example, the
clinicoradiological manifestations of our patient might
have been reasonably and convincingly explained by BAC
and concurrent bacterial infections if Pneumocystis
jiroveci had not been found in the sputum. Similarly, 9
cases of unsuspected active PCP were retrospectively iden-
tified in 50 infants with PCP as presenting manifestation
of severe combined immunodeficiency [15]. Under such
circumstances, close monitoring of peripheral CD4 T lym-
phocyte count and serial examination of respiratory sam-
ples for Pneumocystis jiroveci might be helpful for earlier
diagnosis and improving prognosis.
Conclusion
The present case demonstrated the co-morbidity of PCP in
a chemotherapy and radiotherapy-naïve, HIV-seronega-
tive lung cancer patient with grave clinical outcome.
Prompt diagnosis of PCP as a sequel of lung cancer can be
difficult because of overlap in the clinicoradiological
manifestations, and in the disturbed cellular immunolog-
ical profile. Clinical and microbiological evaluations are
indicated in those at high risk of cellular immunity defi-
ciency, including subjects who undergo prolonged treat-
ment with high dose corticosteroids.
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